Squarepoint
AMLX icon

Squarepoint’s Amylyx Pharmaceuticals AMLX Stock Holding History

Squarepoint’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-114,877
Closed -$1.6M – 4358
2026
Q1 		$1.6M Buy
114,877
+38,315
+50% +$539K ﹤0.01% 2377
2025
Q4 		$925K Buy
+76,562
New +$1.04M ﹤0.01% 2685
2025
Q3 		– Sell
-40,643
Closed -$261K – 4331
2025
Q2 		$261K Sell
40,643
-35,206
-46% -$171K ﹤0.01% 3790
2025
Q1 		$269K Buy
75,849
+565
+0.8% +$2.01K ﹤0.01% 3817
2024
Q4 		$285K Buy
75,284
+27,279
+57% +$128K ﹤0.01% 4192
2024
Q3 		$156K Sell
48,005
-224,571
-82% -$505K ﹤0.01% 3772
2024
Q2 		$518K Buy
272,576
+113,267
+71% +$220K ﹤0.01% 3050
2024
Q1 		$452K Buy
159,309
+125,859
+376% +$1.65M ﹤0.01% 3119
2023
Q4 		$492K Sell
33,450
-6,550
-16% -$100K ﹤0.01% 3013
2023
Q3 		$732K Sell
40,000
-5,810
-13% -$123K ﹤0.01% 2531
2023
Q2 		$988K Sell
45,810
-45,916
-50% -$1.24M ﹤0.01% 2171
2023
Q1 		$2.69M Buy
91,726
+51,726
+129% +$1.8M 0.01% 1238
2022
Q4 		$1.48M Sell
40,000
-1,792
-4% -$63.6K 0.01% 1555
2022
Q3 		$1.18M Buy
+41,792
New +$1.04M 0.01% 1653
2022
Q2 		– Sell
-15,000
Closed -$193K – 2850
2022
Q1 		$193K Buy
+15,000
New +$339K ﹤0.01% 2488

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Squarepoint's AMLX Position: Q2 2026 in Review

Squarepoint sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 114,877 shares — an estimated $1.6M sold.

Squarepoint first reported a position in AMLX in Q1 2022 and held it in 15 quarters. The position peaked at $2.69M in Q1 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Squarepoint reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 114,877 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Squarepoint first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 15 quarters.
  • Squarepoint's Amylyx Pharmaceuticals position peaked at $2.69M in Q1 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.